Pritumumab

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A naturally-produced human immunoglobulin G1 (IgG1) kappa antibody derived from a tumor-specific B-lymphocyte isolated from the regional draining lymph node of a patient with cervical carcinoma and targeted against the cell surface expressed vimentin, ecto-domain vimentin (EDV), with potential immunomodulating and antineoplastic activities. Upon administration, pritumumab targets and binds to EDV, which is expressed on a variety of tumor cell types but is not expressed by normal tissues and cells. This induces tumor cell death by antibody-dependent cell-mediated cytotoxicity (ADCC), and inhibits growth of EDV-expressing tumor cells. Pritumumab is able to penetrate the blood-brain barrier (BBB). Vimentin, an intracellular cytoskeletal protein, is overexpressed during epithelial-to-mesenchymal transition (EMT).

**Synonyms:** - ACA-11 - CLN-IgG - CLNH11 - Immunoglobulin G, Anti-(Human Vimentin) (Human Monoclonal CLN G11 Gamma1-chain), Disulfide With Human Monoclonal CLN G11 Kappa-Chain, Dimer - PRITUMUMAB